Applied TherapeuticsAPLT
About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Employees: 31
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,040% more call options, than puts
Call options by funds: $4.97M | Put options by funds: $436K
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
4% more funds holding
Funds holding: 89 [Q1] → 93 (+4) [Q2]
0.87% less ownership
Funds ownership: 91.76% [Q1] → 90.89% (-0.87%) [Q2]
27% less capital invested
Capital invested by funds: $660M [Q1] → $484M (-$176M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Citigroup Yigal Nochomovitz 57% 1-year accuracy 21 / 37 met price target | 21%upside $11 | Buy Maintained | 19 Sept 2024 |
Leerink Partners Joseph Schwartz 75% 1-year accuracy 6 / 8 met price target | 54%upside $14 | Outperform Maintained | 19 Sept 2024 |
Citigroup Yigal Nochomovitz 57% 1-year accuracy 21 / 37 met price target | 12%downside $8 | Buy Maintained | 27 Aug 2024 |
Financial journalist opinion
Based on 3 articles about APLT published over the past 30 days
